160351-97-3 Usage
Uses
Used in Organic Synthesis:
Cyclobutanecarboxylic acid, 3-hydroxy-, ethyl ester, cis(9CI) is used as a key intermediate in the synthesis of various organic compounds. Its unique molecular structure and reactivity make it a versatile building block for creating complex molecules in the field of organic chemistry.
Used in Porous Materials:
In the field of materials science, Cyclobutanecarboxylic acid, 3-hydroxy-, ethyl ester, cis(9CI) is used as a component in the development of porous materials. Its properties contribute to the creation of materials with specific porosities and functionalities, which can be utilized in applications such as gas storage, separation processes, and catalysis.
Used in Pharmaceutical Manufacturing:
Cyclobutanecarboxylic acid, 3-hydroxy-, ethyl ester, cis(9CI) is employed as a starting material or intermediate in the synthesis of pharmaceutical compounds. Its reactivity and molecular structure make it a valuable asset in the development of new drugs and therapeutic agents.
Used in Chemical Research:
In the realm of chemical research, Cyclobutanecarboxylic acid, 3-hydroxy-, ethyl ester, cis(9CI) serves as a model compound for studying the properties and behavior of cyclobutane derivatives. Its unique molecular geometry and reactivity provide insights into the fundamental aspects of cyclobutane chemistry and contribute to the advancement of the field.
Check Digit Verification of cas no
The CAS Registry Mumber 160351-97-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,0,3,5 and 1 respectively; the second part has 2 digits, 9 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 160351-97:
(8*1)+(7*6)+(6*0)+(5*3)+(4*5)+(3*1)+(2*9)+(1*7)=113
113 % 10 = 3
So 160351-97-3 is a valid CAS Registry Number.
InChI:InChI=1/C7H12O3/c1-2-10-7(9)5-3-6(8)4-5/h5-6,8H,2-4H2,1H3/t5-,6+
160351-97-3Relevant academic research and scientific papers
ISOXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF PULMONARY DISEASES AND DISORDERS
-
Paragraph 0189, (2017/03/21)
The present disclosure features disclosed method of treating disorders such as COPD, bronchitis and/or asthma using disclosed compounds, optionally together with one or more additional active agents. Contemplated methods include administrating orally or by inhalation to a patient one or more disclosed compounds.
COMPOUNDS, COMPOSITIONS AND METHODS FOR INCREASING CFTR ACTIVITY
-
Paragraph 0230, (2016/11/07)
The present disclosure features compounds such as those having the Formulae (Ila), (lIb), (lIc), (Ild), (IlIa), and (Illb), which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The present disclosure also features methods of treating a condition associated with decreased CFTR activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a disclosed compound, such as a compound of Formula (Ila), (lIb), (lIc), (lId), (IlIa), or (Illb).
